– Three patients treated with ZEVASKYN® in Q1 2026 – – QTC network expands to six sites, with two new additions on the East Coast –  – In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized – – $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 – – Webcast today at 8:30am ET – CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN.Steady increase in ZEVASKYN adoption with three patients completing treatment in the first quarter of 2026, one treatment to date in the second quarter, one biopsy currently in...

Revenue grew approximately 35% year-over-year to $15.5 million for Q1 2026 Net income increased by over 100% year-over-year to $2.3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year-over-year to $2.8 million  Remaining performance obligations grew 25% year-over-year to approximately $75 million Shipped a record total of 117 Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Reiterates full-year 2026 financial guidance, including revenue of $66 – $68 million, operating income of 13% – 14%, and Adjusted EBITDA of $12 – $14 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 13, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...

Initial Commercial Rollout Has Commenced with Three Franchisees in Three US States VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, improving food quality, minimizing waste and enhancing sustainability, today announced that it has commenced commercial sales with another medium-sized fast food chain in the United States. This achievement represents another major advancement in Beyond Oil’s U.S. commercial expansion strategy, following an extensive pilot validation program that began in late 2025 and expanded to a multi-location pilot in Q1 of 2026. The pilots demonstrated Beyond Oil’s exceptional performance under...

Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market. “Palvella’s uplisting to the Nasdaq Global Market marks an important milestone in the Company’s continued progress,” said Wes Kaupinen,...

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology PartnersPHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine’s Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell’s ongoing pivotal Phase 3 clinical study (Bria-ABC). BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the independent inclusion...

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) today announced the final distribution for AGF Emerging Markets ex China Fund ETF Series (ticker: AEMX). This final distribution is the result of a previously announced termination of this ETF Series effective close of business on or about May 20, 2026 (the “Termination Date”). Unitholders of record on May 14, 2026 will receive notional distributions payable on May 14, 2026. The final distribution will not be paid in cash but will be reinvested in the form of a notional distribution and reported as taxable. A notional distribution is when the units from a reinvested distribution are immediately consolidated with the units held prior to the distribution. The number of units held after the distribution is therefore identical to the number of units held...

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) — Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential...

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. “We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune,” said Jerry Durso, President and Chief Executive Officer of Altimmune. “As a result of the recent successful financing with top-tier biotech investors, we now have a strong cash position that enables us to focus on execution and delivering...

Q1 2026 Positive Adjusted EBITDA(1) Net Revenue of $9M with strong gross margins of 37% OPEX decreased 28% in Q1 2026 versus Q4 2025 Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ETTORONTO, May 13, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended March 31, 2026 (“Q1 2026”). MediPharm Labs achieved positive adjusted EBITDA(1) in Q1 2026, reflecting disciplined execution and continued cost control aligned with...

Case study presented highlighted clinical experience with revyve® in complex wound care WINNIPEG, Manitoba, May 13, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today its participation in the World Council of Enterostomal Therapists and Nurses Specialized in Wound, Ostomy and Continence Canada (“WCET–NSWOCC”) 2026 Joint Congress, held April 24–28, 2026, in Vancouver, British Columbia. The WCET–NSWOCC Joint Congress brings together global clinical leaders in wound, ostomy and continence care. Kane Biotech participated as an exhibitor and presenter, focusing on educating clinicians on the clinical benefits of revyve Antimicrobial Wound Gel, part of the revyve product family cleared by the U.S. FDA and authorized for sale in Canada. FDA cleared and Health Canada approved...